Bruker said this week that Dirk Laukien has resigned as senior vice president. Separately, it announced that the company's board appointed William Knight as company's chief operating officer and Brian Monahan as chief financial officer.
Laukien's resignation was disclosed in a document filed with the US Securities and Exchange Commission. Bruker said he is resigning to devote more time to personal interests.
He also is resigning from his position as president of Bruker Optics; co-president and director of Bruker BioSpin in the US; and director of Bruker BioSpin AG in Germany. Those resignations took effect on Nov. 11.
Additionally, Laukien is leaving his position as co-CEO of the worldwide Bruker BioSpin group of companies, effective Feb. 1, 2010.
He will remain with Bruker as senior scientific fellow and continue to serve on the company's board. His annual base salary has been reduced to $100,000 effective Nov. 11. The company did not disclose how much he had been making.
Laukien will also remain eligible to receive a cash incentive award as an executive officer in 2009.
The appointments of Knight and Monahan take effect on Feb. 1, 2010.
Knight is presently CFO and Monahan the chief accounting officer of Bruker.
Knight joined the company as treasurer and CFO in 2004. He also is president of the Bruker detection business in the US. Before joining Bruker, he was an operations-focused CFO at several publicly traded companies, and founded ATI Technologies, an analytical instruments firm.
Monahan joined Bruker as corporate controller in 2004 and was appointed chief accounting officer and vice president of finance this past March. He has been executive vice president of Bruker Daltonics since November 2006 and general manager of the Americas since July 2008. He also has held positions as assistant vice president as well as vice president of finance for the Daltonics business. Prior to Bruker, Monahan was at Fisher Scientific where he was manager of accounting and financial reporting.
Oxford BioTherapeutics this week announced additions to its US subsidiary.
Jim Cornett was named chief operating officer of the US operations, while Jon Terrett was appointed vice president for oncology. They join Mike Gresser at the US site, located outside San Jose, Calif. Gresser was recently named chief scientific officer.
Cornett was at Medarex where he served as vice president of business development. Before that, he was at Protein Design Labs as director of business development.
Terrett was previously at Medarex where he helped in the development of drugs using a proteomics platform. Prior to that, he was director of molecular oncology at Oxford Glycosciences, an earlier iteration of OBT.
Gresser is a visiting scholar at the Molecular Biology Institute at the University of California, Los Angeles, and has served on OBT's scientific advisory board since 2007. Prior to joining OBT, he was vice president of research for inflammation at Amgen.